Chronic pain in mice activates Tiam1 in pyramidal neurons in the anterior cingulate cortex, increasing the number of dendritic spines and inducing synaptic plasticity. Ketamine's antidepressant effect in chronic pain is mediated by the drug blocking Tiam1-dependent maladaptive synaptic plasticity in ACC neurons.
Ketamine treatment leads to an increase in IGF-1, which, in turn, produces an antidepressant effect.
NV-5138, a small molecule drug that mimics the action of ketamine, provides fast-acting antidepressant responses in rodent models of depression. The drug is currently undergoing Phase 1 testing in humans.
A new study reports aerobic exercise can have antidepressant effects for patients with major depressive disorder.
Researchers report physical exercise failed to promote antidepressant-like effects in mice genetically engineered to express a human genetic variation in the gene BDNF.
A metabolite created as the body breaks down ketamine could hold the key to understanding its antidepressant action, a new study reports.
Researchers report those addicted to cocaine may have difficulty controlling their addiction because of a 'back door' into the brain that circumvents their self control.
New understanding about ketamine's antidepressant effect could lead to the development of new, safer and quicker ways to treat depression.